Endocrine Abstracts

Background: BRAFK601E mutation is a class 2 oncogenic BRAF mutation which causes constitutive activation of MAPK pathway functioning as RAS-independent activated dimers. In thyroid cancer, the BRAFK601E is more rare than the BRAFV600E, and it has been mostly associated to clinically indolent follicular architecture neoplasms. This is a mono-institutional study aimed at evaluating the frequency and clinical ro...